Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide for weight loss in hypothalamic obesity after craniopharyngioma
2014-000871-17Phase 4Active
- Sponsor
- Eva Marie Erfurth
- Start
- Jun 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, single-arm trial of exenatide in hypothalamic obesity (HO) and craniopharyngioma, sponsored by Eva Marie Erfurth. Primary endpoint: Weight reduction. Started Jun 2014; status: active.
02
Drugs
exenatide
03
Conditions
hypothalamic obesity (HO)craniopharyngioma
Beyond the preview
Go deeper on 2014-000871-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000871-17.